Absci Corporation (ABSI)
NASDAQ: ABSI · Real-Time Price · USD
3.140
+0.240 (8.28%)
Mar 14, 2025, 4:00 PM EST - Market closed
Absci Revenue
Absci had revenue of $1.70M in the quarter ending September 30, 2024, with 128.63% growth. This brings the company's revenue in the last twelve months to $4.21M, down -39.35% year-over-year. In the year 2023, Absci had annual revenue of $5.72M, down -0.50%.
Revenue (ttm)
$4.21M
Revenue Growth
-39.35%
P/S Ratio
78.10
Revenue / Employee
$27,142
Employees
155
Market Cap
360.65M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 5.72M | -29.00K | -0.50% |
Dec 31, 2022 | 5.75M | 965.00K | 20.18% |
Dec 31, 2021 | 4.78M | 2.00K | 0.04% |
Dec 31, 2020 | 4.78M | 2.72M | 132.04% |
Dec 31, 2019 | 2.06M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
ABSI News
- 11 days ago - Absci to Report Business Updates and Fourth Quarter and Full Year 2024 Financial and Operating Results on March 18, 2025 - GlobeNewsWire
- 11 days ago - Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 12 days ago - Absci to Participate in the KeyBanc Capital Markets Healthcare Forum - GlobeNewsWire
- 26 days ago - Absci to Participate in the TD Cowen 45th Annual Health Care Conference - GlobeNewsWire
- 7 weeks ago - Analyst Praises AMD-Partner Absci's Practical Approach, Sees 118% Stock Upside - Benzinga
- 7 weeks ago - Absci to Participate in the Guggenheim Securities SMID Cap Biotech Conference - GlobeNewsWire
- 2 months ago - Absci Looks Cheap And Positioned For Growth With AMD's AI Backing - Seeking Alpha
- 2 months ago - Absci and Owkin Synergize Leading TechBio Platforms to Advance Generative AI Drug Discovery - GlobeNewsWire